Cargando…
Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study
Background: Early treatment with remdesivir (RMD) or monoclonal antibodies (mAbs) could be a valuable tool in patients at risk of severe COVID-19 with unsatisfactory responses to vaccination. We aim to assess the safety and clinical outcomes of these treatments among immunocompromised subjects. Meth...
Autores principales: | Biscarini, Simona, Villa, Simone, Genovese, Camilla, Tomasello, Mara, Tonizzo, Anna, Fava, Marco, Iannotti, Nathalie, Bolis, Matteo, Mariani, Bianca, Valzano, Antonia Grazia, Morlacchi, Letizia Corinna, Donato, Francesca, Castellano, Giuseppe, Cassin, Ramona, Carrabba, Maria, Muscatello, Antonio, Gori, Andrea, Bandera, Alessandra, Lombardi, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405567/ https://www.ncbi.nlm.nih.gov/pubmed/36009549 http://dx.doi.org/10.3390/biomedicines10082002 |
Ejemplares similares
-
Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients
por: Lombardi, Andrea, et al.
Publicado: (2023) -
Nocardia Infections in the Immunocompromised Host: A Case Series and Literature Review
por: Palomba, Emanuele, et al.
Publicado: (2022) -
Mucormycosis in CAPA, a Possible Fungal Super-Infection
por: Saltini, Paola, et al.
Publicado: (2021) -
Multidrug-Resistant Gram-Negative Bacteria Decolonization in Immunocompromised Patients: A Focus on Fecal Microbiota Transplantation
por: Alagna, Laura, et al.
Publicado: (2020) -
Gut and airway microbiota dysbiosis and their role in COVID-19 and long-COVID
por: Ancona, Giuseppe, et al.
Publicado: (2023)